Up to 70% of breast cancers show ERα expression, and two-thirds of ERα-positive breast carcinoma patients respond to treatment with anti-estrogen therapy [2-4], while breast cancer lacking ERα expression does not benefit from endocrine treatment. The gene discussed is ESR1; the disease is breast carcinoma.